Disclosure: We publish this comparison because we are LevelsRx, so we have a direct financial interest in how our program is presented. We have tried to keep the comparison factual and based on current LevelsRx program information and publicly available MEDVi information checked on August 31, 2026. This is not independent testing, does not compare clinical outcomes, and is for informational purposes only. Medication eligibility and treatment decisions belong to a licensed healthcare provider.
In This Guide
- How we compared LevelsRx and MEDVi
- LevelsRx vs MEDVi at a glance
- How pricing and price stability differ
- Medication options and treatment pathways
- Clinician access and ongoing support
- Insurance, HSA/FSA, and cash-pay access
- Where our LevelsRx model stands out
- Where MEDVi may be a better fit
- Questions to ask before enrolling
- Frequently asked questions
- The bottom line
Key Takeaways
Q: What is the biggest practical difference between LevelsRx and MEDVi? A: The two programs are more similar than many telehealth comparisons because both offer cash-pay GLP-1 pathways with clinician review and bundled support. Our current Compounded Semaglutide (GLP-1) offer is $88 for the first month, while MEDVi currently markets several promotional and price-lock offers whose exact pricing can vary by landing page.
Q: Which program is cheaper? A: Our current first-month Compounded Semaglutide (GLP-1) price is $88. One MEDVi price-lock page checked on August 31, 2026 advertises semaglutide injection at $116 per month and tirzepatide injection at $166 per month, but other MEDVi page copy references different promotional or refill prices. Because our post-first-month price and MEDVi’s exact offer can vary, patients should compare the checkout terms that apply to them rather than assuming one provider is always cheaper.
Q: How does clinician support compare? A: We advertise same-day access to licensed clinicians and unlimited online video visits, along with 1:1 nutritionist coaching and ongoing chat support. MEDVi advertises 24/7 support, unlimited appointments and messaging, physician guidance, care coaching, and dietitian support. In this comparison, support is a strength of both programs rather than a clear one-sided advantage.
Q: Do both programs offer compounded GLP-1 medications? A: Yes, when a licensed clinician determines that treatment is appropriate. Both programs publicly discuss compounded GLP-1 pathways. Compounded medications are not FDA-approved, and patients should understand the regulatory distinction, source pharmacy, formulation, and clinical rationale before treatment.
Q: When may MEDVi be the stronger fit? A: MEDVi may appeal to someone who values its advertised price-lock offers, explicit HSA/FSA positioning, 24/7 support model, bundled shipping, or a specific MEDVi medication pathway. The right fit depends on the actual offer available, the medication a clinician recommends, and the support model a patient prefers.
How we compared LevelsRx and MEDVi
We compared the parts of each weight-management program a prospective patient can evaluate before enrolling: current advertised pricing, what the advertised fee includes, medication pathways, clinician access, coaching, insurance dependence, payment flexibility, and ongoing support.
For our own program, we used current LevelsRx program information together with information published at LevelsRx.com. For MEDVi, we reviewed its GLP-1 program page, a current price-lock offer page, its patient-care site, and its first-party terms and disclosures. Details were checked on August 31, 2026. Pricing, promotions, medication availability, and program terms can change, so readers should verify the offer shown at checkout before enrolling.
We do not assign ourselves a clinical score or claim better weight-loss outcomes. The purpose is to explain the practical tradeoffs in cost, access, medication pathways, and support. For a broader framework, see our guide to what to look for in a telehealth GLP-1 provider.
LevelsRx vs MEDVi at a glance
| Factor | Our LevelsRx program | MEDVi |
| Current advertised semaglutide entry price | Our Compounded Semaglutide (GLP-1) is $88 for the first month. | A price-lock page checked August 31, 2026 advertises semaglutide injection at $116/month, although other MEDVi page copy references different promotional or refill figures. Verify the exact checkout offer. |
| Pricing model | Bundled cash-pay treatment model with clinical access and support; our current FAQ states there are no separate membership costs within the subscription services. | MEDVi’s compounded-treatment pages advertise no membership or hidden fees, with medication, physician review, guidance, and shipping included. Some brand-name pathways are displayed separately as a membership plus medication cost. |
| Clinician access | We advertise same-day access to licensed clinicians and unlimited online video visits. | MEDVi says independent licensed clinicians review eligibility and prescriptions, with 24/7 support and unlimited appointments and messaging. |
| Coaching and nutrition support | 1:1 nutritionist coaching, ongoing chat support, virtual consultations, and health guidance are part of our current care model. | MEDVi advertises care coaching, dietitian support, physician guidance, and an all-in-one patient portal. |
| Medication pathways | Our current program prominently lists compounded semaglutide, compounded tirzepatide, and oral compounded semaglutide, subject to clinician review. We also help patients explore brand-name coverage when relevant. | MEDVi publicly markets compounded semaglutide and tirzepatide, including injectable and tablet pathways. Some current landing pages also display Wegovy and Zepbound pathways, with availability subject to change. |
| Insurance dependence | Our compounded cash-pay pathway does not require insurance approval; insurance support may be used when exploring relevant brand-name options. | MEDVi markets its compounded pathways as cash-pay with no insurance required. Its pages state insurance may be relevant to branded options, but patients should verify the exact pathway and reimbursement rules. |
| Other payment features | Patients should verify current checkout and payment terms. | MEDVi explicitly advertises HSA/FSA eligibility on current GLP-1 landing pages and some offers use a price-lock model. |
The key point is that this is not a comparison between a bundled provider and a low-cost membership that charges medication separately. LevelsRx and MEDVi both market bundled cash-pay GLP-1 care. The more useful questions are therefore the exact medication and price offered to you, how price changes are handled, what kind of clinician access you want, and which support services matter most.
How pricing and price stability differ
Our LevelsRx pricing model
As of August 31, 2026, our Compounded Semaglutide (GLP-1) treatment is $88 for the first month. Our current program is designed around bundled care rather than a separate platform membership plus medication fee. We also include regular clinician access and support services within the care model.
We are deliberately not publishing an assumed post-first-month semaglutide price here because patients should compare the actual terms shown at checkout. For any GLP-1 program, the useful number is the expected total cost over the period you expect to use the service, not only the introductory price. Our guide to what GLP-1 weight loss actually costs explains how to compare program fees, medication, labs, and other expenses together.
MEDVi pricing model
MEDVi’s current compounded-treatment pages also use a bundled cash-pay model. One price-lock landing page checked on August 31, 2026 advertises $116 per month for semaglutide injection and $166 per month for tirzepatide injection, with no membership fee, free shipping, and a promise that the listed price will not increase.
However, MEDVi’s current first-party pages are not perfectly consistent with one another: other FAQ and promotional copy can display different introductory or refill figures. That does not necessarily mean the offer is misleading; telehealth brands commonly run multiple promotions and acquisition pages. It does mean a comparison article should not treat one MEDVi landing-page number as a universal price. Verify the medication, dose policy, recurring price, commitment period, cancellation terms, and any promotion directly at checkout.
Medication options and treatment pathways
Our current LevelsRx program prominently lists compounded semaglutide, compounded tirzepatide, and oral compounded semaglutide options when clinically appropriate. We also help patients explore brand-name coverage when a licensed provider determines that a brand-name medication is appropriate and insurance is relevant.
MEDVi’s current GLP-1 pages likewise emphasize compounded semaglutide and tirzepatide, including injection and tablet options. Some MEDVi landing pages also display brand-name Wegovy and Zepbound pathways under a different pricing structure, with availability expressly subject to change.
What both programs should make clear about compounded medications
The FDA states that compounded drugs are not FDA-approved. The agency does not review compounded products for safety, effectiveness, or quality before marketing in the same way it reviews FDA-approved drugs. FDA also says compounded drugs should generally be used when a patient’s medical needs cannot be met by an FDA-approved drug.
That distinction applies regardless of which telehealth platform facilitates the prescription. Patients should ask which pharmacy will dispense the medication, what formulation is being prescribed, why the clinician believes it is appropriate, and what alternatives are available. Our guide to compounded GLP-1 alternatives covers this issue in more detail.
Clinician access and ongoing support
Support is one area where both services make substantial promises, so the distinction is more about format than whether support exists at all.
Our LevelsRx support model
We currently advertise same-day access to licensed clinicians and unlimited online video visits. Our care model also includes regular virtual consultations, prescription management and renewals when applicable, 1:1 nutritionist coaching, ongoing chat support, and health guidance.
For a patient who wants face-to-face video access without treating each question as a separate paid appointment, that can be an important part of the decision. It is also useful when discussing tolerability, progress, nutrition, or whether a clinician needs to reassess treatment.
MEDVi support model
MEDVi’s current pages state that an independent licensed clinician reviews the patient’s information and retains the prescribing decision. MEDVi advertises 24/7 support, unlimited appointments and messaging, 1:1 physician guidance, care coaching, dietitian support, and a patient portal for managing care.
Those are meaningful support features. A prospective patient should go one level deeper and ask how quickly a prescribing clinician can be reached, whether support is synchronous or asynchronous, whether video visits are available when requested, and what happens if significant side effects or treatment questions arise. For general guidance, see our article on managing GLP-1 side effects.
Insurance, HSA/FSA, and cash-pay access
Both LevelsRx and MEDVi make it possible to consider a compounded cash-pay pathway without waiting for an insurer to approve a weight-loss medication. That can simplify access for patients whose plans exclude weight-management drugs or impose difficult prior-authorization requirements.
MEDVi explicitly advertises HSA/FSA eligibility on current GLP-1 landing pages. It also states that no insurance is required for its compounded programs. Some MEDVi pages mention brand-name medication pathways separately, so patients considering those options should confirm whether the medication is cash-pay, potentially reimbursable, or processed through insurance.
Our LevelsRx model similarly provides a cash-pay compounded pathway while helping patients explore insurance coverage when a relevant brand-name medication is being considered. Neither platform can guarantee that an insurer will cover a particular medication. Coverage depends on the plan, diagnosis, medication, prior-authorization requirements, and other insurer rules.
Where our LevelsRx model stands out
Because MEDVi also offers a bundled cash-pay model and substantial support, our strongest advantages are specific rather than universal.
- Lower current first-month semaglutide entry price: our Compounded Semaglutide (GLP-1) is currently $88 for the first month, below the $116/month semaglutide price displayed on the MEDVi price-lock page we checked.
- Same-day clinician access: we explicitly advertise same-day access to licensed clinicians.
- Unlimited video visits: our model emphasizes direct online video access rather than only general support or messaging availability.
- Integrated nutrition support: 1:1 nutritionist coaching is part of our current care model alongside ongoing chat and clinical follow-up.
These are program-structure advantages, not evidence that LevelsRx produces better medical outcomes. Individual results depend on the medication, patient, adherence, medical history, lifestyle, and care delivered.
Where MEDVi may be a better fit
MEDVi has several features that may reasonably make it the better choice for some patients.
- Price-lock preference: if the specific offer you qualify for includes MEDVi’s advertised price-lock guarantee, knowing the recurring price will not increase may matter more than paying the lowest introductory price.
- HSA/FSA use: MEDVi explicitly promotes HSA/FSA eligibility on current GLP-1 pages.
- 24/7 support positioning: MEDVi advertises round-the-clock support, unlimited appointments, and messaging.
- Specific MEDVi treatment pathway: a patient may simply prefer a medication, pharmacy arrangement, portal experience, or brand-name option available through MEDVi after clinician review.
The correct decision is not “which company has the longest feature list.” It is which verified offer, medication pathway, clinical relationship, and support format best match the patient’s needs.
Questions to ask before enrolling
Before paying either provider, we recommend getting clear answers to the same practical questions:
- What is the exact medication and formulation being considered, and is it FDA-approved or compounded?
- What will I pay in the first month, and what is the recurring price after any promotion?
- Is medication, shipping, clinician review, coaching, and follow-up included in that price?
- How can I reach the prescribing clinician if I have side effects or treatment questions?
- Can the price change as my dose or treatment plan changes?
- Which pharmacy will dispense a compounded prescription, if one is prescribed?
- What are the cancellation, renewal, refund, and shipping terms?
If you are comparing several services rather than only these two, our broader guide to choosing a GLP-1 provider in 2026 can help you compare the same factors consistently.
Frequently asked questions
For the first month of compounded semaglutide, our current LevelsRx price is $88. A MEDVi price-lock page checked August 31, 2026 advertises semaglutide injection at $116 per month. That does not prove LevelsRx is always cheaper because our post-first-month price and MEDVi promotions can vary. Compare the exact recurring checkout terms that apply to you.
MEDVi’s current compounded-treatment pages say medication, physician review, guidance, and shipping are included and advertise no separate membership or hidden fees. MEDVi also displays some brand-name pathways under a different membership-plus-medication pricing structure, so verify the exact program before enrolling.
Both offer cash-pay GLP-1 pathways with clinician review and ongoing support. Our LevelsRx model currently emphasizes an $88 first month for Compounded Semaglutide (GLP-1), same-day licensed-clinician access, unlimited video visits, 1:1 nutritionist coaching, and ongoing chat. MEDVi emphasizes price-lock offers, 24/7 support, unlimited appointments and messaging, dietitian and care coaching, free shipping, and HSA/FSA eligibility.
No. Compounded drugs are not FDA-approved. FDA does not review compounded products for safety, effectiveness, and quality before marketing in the same way it reviews approved drugs. A licensed clinician should determine whether a compounded medication is appropriate for a patient’s medical needs.
MEDVi may be a better fit if you value a qualifying price-lock offer, explicit HSA/FSA eligibility, 24/7 support positioning, unlimited appointments and messaging, or a specific medication pathway available through MEDVi. Verify the actual offer and clinical pathway before enrolling.
The bottom line
LevelsRx and MEDVi are closer competitors than many telehealth brands because both offer bundled cash-pay GLP-1 pathways with clinician review and ongoing support. Our current $88 first-month Compounded Semaglutide (GLP-1) offer gives us a lower entry price than the $116 semaglutide price on the MEDVi price-lock page we checked, while MEDVi’s advertised price lock, HSA/FSA eligibility, 24/7 support, and bundled shipping may be meaningful advantages for some patients.
The best choice depends on the exact offer available, the medication a licensed clinician determines is appropriate, the pharmacy and formulation involved, the support format you prefer, and the total recurring cost. Neither platform should be chosen on headline price alone, and neither can guarantee a particular medical outcome.
